Developing and implementing innovative Patient-Centred Care Pathways for cancer patients

Despite advances in early detection and new therapies, higher cure rates and more patients living longer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important.

However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine.

MyPath project aims to develop technology-enhanced and evidence-based patient-centred care pathways, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. MyPath will integrate patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to deliver the right care to the right person at the right time by the right persons.

Therefore, MyPath will be crucial in order to improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancer.

The European consortium

MyPath consortium is made up of 15 project partners, including 9 clinical partners from 8 European countries. Partners entities are Oslo Universitetssykehus HF from Norway (Coordinator), Fondazione Irccs Istituto Nazionale dei Tumori from Italy, Vrije Universiteit Brussel from Belgium, Fundación para la Investigación del Hospital Clínico de la Comunitat Valenciana, Fundación Incliva (INCLIVA) from Spain, Region Hovedstaden from Denmark, Klinikum Ernst von Bergmann Gemeinnutzige GMBH from Germany, Fundatia Hospice Casa Sperantei from Romania, DNV Imatis AS from Norway, European Association of Palliative Care and European Cancer Patient Coalition from Belgium. In addition, the consortium includes five associated partners: Accelopment Schweiz AG and European Society for Medical Oncology which are located in Switzerland; The University of Edinburgh, University of Leeds and The Leeds Teaching Hospitals National Health Service Trust located in the UK.

INCLIVA’s role

INCLIVA will participate in the structure and contents co-design as pilot site, in the ICT Digital solution development and configuration, in the development of a health economic model, in the evaluation of the proposed model and measure its outcomes and within its Large-scale implementation and validation, and finally, in the training of the staff involved on ethical and legal aspects.




Prof. Dr. Andrés Cervantes




388.125,00 €